872679-70-4

Basic information

• Product Name: Fmoc-9-Amino-4,7-Dioxanonanoic acid
• Synonyms: 9-[(9H-Fluoren-9-ylmethoxy)carbonylamino]-4,7-dioxanonanoic Acid;Fmoc-N-amido-PEG2-acid;Fmoc-PEG2- CH2CH2COOH;Fmoc-PEG2-propionic acid;Fmoc-AEEP-OH≥ 98% (HPLC);Fmoc-AEEP;FMoc-NH-PEG2-CH2CH2COOH;1-(9H-Fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azatridecan-13-oic acid
• CAS NO: 872679-70-4
• Molecular Formula: C₂₂H₂₅NO₆
• Molecular Weight: 399.437
• Mol File: 872679-70-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 95.0 to 99.0 °C
• Boiling Point: 621.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.243±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• PKA: 4.28±0.10(Predicted)
• CAS DataBase Reference: Fmoc-9-Amino-4,7-Dioxanonanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Fmoc-9-Amino-4,7-Dioxanonanoic acid(872679-70-4)
• EPA Substance Registry System: Fmoc-9-Amino-4,7-Dioxanonanoic acid(872679-70-4)

Safety Data

• Hazardous Substances Data: 872679-70-4(Hazardous Substances Data)

Usage

Description

Fmoc-N-amido-PEG2-acid is a PEG linker containing an Fmoc-protected amine and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The Fmoc group can be deprotected under basic condition to obtain the free amine which can be used for further conjugations. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond.

Chemical Properties

White crystalline powder

Uses

Fmoc-AEEP-OH is used in preparation of glucose-responsive insulin conjugates.

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 756525-95-8 2-methyl-2-propanyl 3-[2-(2-aminoethoxy)ethoxy]propanoate 

Downstream Products

• 791028-27-8 amino-PEG(2u)-acid 

Relevant articles and documents

Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes

The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficacy model data are discussed. A proposed protein–ligand binding mode for this compound is also provided to rationalise the high levels of potency and selectivity over inhibition of related sodium channels. To further support the proposed binding mode, potent conjugates are described which illustrate the potential for development of chemical probes to enable further target evaluation.